Bacillus (e.g., B. Subtilis, B. Thuringiensis, Etc.) Patents (Class 435/252.31)
-
Publication number: 20140322812Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: April 24, 2014Publication date: October 30, 2014Applicant: Intrexon CorporationInventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
-
Publication number: 20140322768Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140325711Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 23, 2012Publication date: October 30, 2014Inventors: Kirk Matthew Schnorr, Jens Erik Nielsen, Mikkel Klausen
-
Publication number: 20140322753Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: June 30, 2014Publication date: October 30, 2014Inventors: Paul Harris, Elena Vlasenko, Marcus Sakari Kauppinnen, Elizabeth Zaretsky, Sarah Teter, Kimberly Brown
-
Publication number: 20140322778Abstract: The expression vector includes: the nucleic acids coding for the polypeptides forming a polypeptide complex having an enzyme activity allowing acetoacetyl-CoA to be converted to acetoacetate; optionally, at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetoacetate to be converted to acetone; and at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetone to be converted to isopropanol; the expression of the nucleic acids being controlled by a single constitutive promoter located upstream of the abovementioned nucleic acids.Type: ApplicationFiled: October 3, 2012Publication date: October 30, 2014Applicant: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEKInventors: Florent Collas, Remy Marchal, Benjamin Clement, Ana Maria Lopez Contreras, Pieternel A.M Claassen
-
Publication number: 20140322755Abstract: The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi.Type: ApplicationFiled: June 25, 2012Publication date: October 30, 2014Inventor: Tom Tao Huang
-
Publication number: 20140322224Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Applicant: ALPER BIOTECH LLCInventor: Ozge Alper
-
Publication number: 20140322221Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.Type: ApplicationFiled: March 28, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Kathy L. MILLER, Leonard G. PRESTA
-
Patent number: 8871489Abstract: This invention relates to the metabolic evolution of a microbial organism previously optimized for producing an organic acid in commercially significant quantities under fermentative conditions using a hexose sugar as sole source of carbon in a minimal mineral medium. As a result of this metabolic evolution, the microbial organism acquires the ability to use pentose sugars derived from cellulosic materials for its growth while retaining the original growth kinetics, the rate of organic acid production and the ability to use hexose sugars as a source of carbon. This invention also discloses the genetic change in the microorganism that confers the ability to use both the hexose and pentose sugars simultaneously in the production of commercially significant quantities of organic acids.Type: GrantFiled: November 17, 2010Date of Patent: October 28, 2014Assignee: Myriant CorporationInventors: Tammy Grabar, Wei Gong, R. Rogers Yocum
-
Patent number: 8871488Abstract: The present invention is related to recombinant host cells comprising: (i) at least one deletion, mutation, and/or substitution in an endogenous gene encoding a polypeptide that converts pyruvate to acetaldehyde, acetyl-phosphate or acetyl-CoA; and (ii) a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity. The present invention is also related to recombinant host cells further comprising (iii) a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity.Type: GrantFiled: June 15, 2011Date of Patent: October 28, 2014Assignee: Butamax Advanced Biofuels LLCInventors: Michael Dauner, Lori Ann Maggio-Hall, Jean-Francois Tomb
-
Patent number: 8871441Abstract: The invention provides methods of screening a microbial host cell for a property of interest in a microfluidic device, the method comprising the steps of: a) transforming a d-alanine racemase-deficient microbial host cell with a polynucleotide construct comprising: i) one or more polynucleotide region providing the property of interest when present in the host cell, and ii) at least one polynucleotide region complementing the d-alanine racemase deficiency when present in the host cell; and b) screening the transformed host cell for the property of interest in the microfluidic device in the absence of externally provided d-alanine.Type: GrantFiled: August 14, 2009Date of Patent: October 28, 2014Assignee: Novozymes A/SInventors: Thomas Lenhard, Mads Eskelund Bjoernvad, Poul Erik Pedersen
-
Publication number: 20140314718Abstract: The present invention relates to an isolated strain of Bacillus subtilis (IAB/BS/03) deposited at the DSM German Type Culture Collection under Access No DSM 24682, or a mutant of said strain, and also deposited at the Spanish type culture collection under Access number CECT 7254, the property of the company filing the patent, in which said strain and/or the mutant thereof exhibits antifungal and antibacterial activity, with a profile of action different from that of other strains of Bacillus subtilis and with much greater potency in terms of the capacity thereof to act as a field biological control agent. The invention also includes methods for preventing and treating fungal and bacterial diseases in plants using said bacterial strains or supernatants containing antibiotics or pure antibiotics obtained from said bacterial strains, in which said antibiotics are contained in a composition.Type: ApplicationFiled: May 4, 2012Publication date: October 23, 2014Inventors: Estefania Hinarejos Esteve, Raquel Del Val Buedo, Nuria Tarancon Valera, Enrique Riquelme Terres
-
Publication number: 20140314716Abstract: The invention relates to a Bacillus anthracis (B. anthracis) in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. The disclosure provides a B. anthracis that comprises a genetic modification that inactivates a protease of the M4 family of metallopro teases and a genetic modification that inactivates a protease of the M6 family of metalloproteases. Also provided is a modified B. anthracis comprising such genetic modification transformed with a recombinant molecule encoding a product, as well as methods to prepare and use such B. anthracis.Type: ApplicationFiled: August 2, 2012Publication date: October 23, 2014Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SEC, OF DEPT OF HEALTH AND HUMAN SERVICESInventors: Andrei P. Pomerantsev, Stephen H. Leppla
-
Publication number: 20140315310Abstract: The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells.Type: ApplicationFiled: December 13, 2013Publication date: October 23, 2014Applicant: Massachusetts Institute of TechnologyInventors: Timothy Kuan-Ta Lu, Piro Siuti
-
Publication number: 20140315278Abstract: This invention discloses novel bacterial spore systems. Genetically modified or genetically engineered viable spore systems expressing bioactive polypeptides, for example bacteriocins and/or enzymatically active feed enzymes, at the spore surface, have a great potential use in animal feeding. Genetically modified or “genetically engineered inert spore systems expressing affinity ligands or immobilized enzymes at the surface have a great potential use in biocatalysis and in the construction of biocatalytic films. Especially the resistance to harsh chemicals, desiccation, strong pressure, or high temperatures allows the spores to be a potentially valuable tool for the display of bioactive molecules, like biocatalytic enzymes or bioactive feed enzymes that must survive harsh conditions to deliver their full potential.Type: ApplicationFiled: March 26, 2014Publication date: October 23, 2014Applicant: DSM IP Assets B.V.Inventors: Adriano O. HENRIQUES, Ghislain Schyns, Thibaut José Wenzel, Sebastien Potot
-
Publication number: 20140317786Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Inventor: Marc Morant
-
Publication number: 20140314832Abstract: The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.Type: ApplicationFiled: August 2, 2013Publication date: October 23, 2014Applicant: Shanghai Pulmonary Hospital, Tongji University School of MedicineInventors: Huiping Li, Shanmei Wang
-
Publication number: 20140315775Abstract: The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved stability in the presence of a metal chelator. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications comprising citrate. In some particularly preferred embodiments, the present invention provides methods and compositions comprising variant neutral metalloprotease(s) engineered to resist citrate-induced autolysis.Type: ApplicationFiled: February 24, 2014Publication date: October 23, 2014Applicant: Danisco US Inc.Inventors: RONALDUS W.J. HOMMES, AMY D. LIU, ANDREW SHAW, LOUISE WALLACE
-
Publication number: 20140309405Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.Type: ApplicationFiled: March 26, 2014Publication date: October 16, 2014Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
-
Publication number: 20140308271Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.Type: ApplicationFiled: January 2, 2014Publication date: October 16, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
-
Publication number: 20140308267Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. The invention further pertains to polypeptides encoded by the polynucleotide of the invention as well as polypeptides comprising one or more amino acid substitutions. Further encompassed by the present invention are vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: ApplicationFiled: November 8, 2012Publication date: October 16, 2014Inventors: Michael Schmidt, Jurge Frevert, Fred Hofmann, Gerhard Groer
-
Publication number: 20140308266Abstract: The present invention is concerned with modified neurotoxins. Specifically, it relates to a modified biologically active neurotoxin polypeptide comprising at least one poly-Glycine domain. Also contemplated is a polynucleotide encoding the modified neurotoxin polypeptide having a poly-Glycine domain fused to the N-terminus, to the C-terminus or to both of the heavy and/or light chain of the mature neurotoxin polypeptide, vector comprising it and a host cell comprising such a polynucleotide or a vector. Moreover, envisaged are the aforementioned compounds for use as a medicament for treating various diseases.Type: ApplicationFiled: November 8, 2012Publication date: October 16, 2014Inventor: Karl-Heinz Eisele
-
Publication number: 20140308285Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.Type: ApplicationFiled: March 12, 2014Publication date: October 16, 2014Applicant: Amgen Inc.Inventors: Wei YAN, Martin J. PENTONY, Luis G. BORGES, Mark L. MICHAELS
-
Publication number: 20140302040Abstract: The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof.Type: ApplicationFiled: May 15, 2013Publication date: October 9, 2014Inventors: Satomichi Yoshimura, Tatsuya Kurihara, Kayoko Kawashima, Masato Hoshino, Kumiko Kadoshima, Maki Tsujimoto, Takako Kimura, Jun Hasegawa
-
Publication number: 20140302037Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.Type: ApplicationFiled: March 13, 2014Publication date: October 9, 2014Applicant: Amgen Inc.Inventors: Luis G. BORGES, Patrick A. BAEUERLE, Wei YAN, Mark L. MICHAELS
-
Publication number: 20140302076Abstract: The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunise an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere.Type: ApplicationFiled: August 13, 2012Publication date: October 9, 2014Applicant: THE UNIVERSITY OF QUEENSLANDInventors: Anton Peter Jacob Middelberg, Linda Hwee-Lin Lua
-
Publication number: 20140301946Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140302016Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: ApplicationFiled: June 19, 2014Publication date: October 9, 2014Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
-
Publication number: 20140302590Abstract: The present invention provides protease compositions particularly suited for dishwashing applications.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Applicant: Danisco US Inc.Inventors: Pieter Augustinus, Frits Goedegebuur, Ayrookaran J. Poulose, Johannes C. Van Der Laan
-
Publication number: 20140304859Abstract: Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 14, 2012Publication date: October 9, 2014Applicant: Novozymes Inc.Inventors: Ye Liu, Yu Zhang, Junxin Duan, Lan Tang
-
Publication number: 20140302574Abstract: Methods and materials related to producing 3-HP as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-HP and other organic compounds are disclosed.Type: ApplicationFiled: June 17, 2014Publication date: October 9, 2014Applicant: Cargill, IncorporatedInventors: Ravi R. Gokarn, Olga V. Selifonova, Holly Jean Jessen, Steven John Gort, Thorsten Selmer, Wolfgang Buckel
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Patent number: 8852903Abstract: Recombinant microorganisms having an improved ability to co-metabolize in medium both fructose and glucose are described. The recombinant microorganisms comprise a promoter operably linked to a native or non-native nucleotide sequence that encodes a fucose: H+ symporter polypeptide. The recombinant microorganisms are useful for the production of a variety of products including glycerol and glycerol derivatives such as 1,3-propanediol and 3-hydroxypropionic acid.Type: GrantFiled: October 18, 2010Date of Patent: October 7, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Andrew C. Eliot, Anthony A. Gatenby, John S. Chapman
-
Publication number: 20140295526Abstract: This invention relates to modified polynucleotides encoding modified proteases, and methods for altering the production of proteases in microorganisms. In particular, the present invention relates to methods for altering the expression of proteases in microorganisms, such as Bacillus species. The invention discloses modified polynucleotides, vectors, modified polypeptides, and processes for enhancing the production of proteases.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Applicant: DANISCO US INC.Inventors: Eugenio FERRARI, David A. ESTELL
-
Publication number: 20140294867Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 10, 2014Publication date: October 2, 2014Applicant: Genzyme CorporationInventors: Clark PAN, Qun ZHOU, James STEFANO, Pradeep DHAL, Bo CHEN, Diego GIANOLIO, Robert MILLER, Huawei QIU
-
Publication number: 20140294881Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.Type: ApplicationFiled: September 18, 2008Publication date: October 2, 2014Applicant: Danisco US Inc.Inventors: David A. Estell, Fiona A. Harding, Ayrookaran J. Poulose
-
Publication number: 20140295544Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventor: Khalid S. Abu KHABAR
-
Publication number: 20140295502Abstract: The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention.Type: ApplicationFiled: May 13, 2014Publication date: October 2, 2014Inventors: Wu-Bo LI, Joel Jessee, Christian Gruber
-
Publication number: 20140298505Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: ApplicationFiled: June 6, 2012Publication date: October 2, 2014Inventor: Ralf Kühn
-
Publication number: 20140295556Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.Type: ApplicationFiled: March 14, 2014Publication date: October 2, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: J. Keith Joung, Shengdar Tsai
-
Patent number: 8846403Abstract: The invention describes a method of screening for protein secreting recombinant host cells comprising screening for promoter activity of a stress inducible promoter. The method can be used for rapid identification of actively secreting transformants and can be used to screen recombinant libraries for transformants secreting proteins.Type: GrantFiled: October 13, 2004Date of Patent: September 30, 2014Assignee: Novozymes A/SInventor: Tine Hoff
-
Publication number: 20140287465Abstract: The present invention relates to polypeptides having xylanase activity, catalytic domains, and carbohydrate binding domains, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding domains. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding domains.Type: ApplicationFiled: December 18, 2012Publication date: September 25, 2014Inventors: Nikolaj Spodsberg, Tarana Shaghasi
-
Publication number: 20140287471Abstract: The present disclosure relates to variant CBH I polypeptides that have reduced product inhibition, and compositions, e.g., cellulase compositions, comprising variant CBH I polypeptides. The variant CBH I polypeptides and related compositions can be used in variety of agricultural and industrial applications. The present disclosure further relates to nucleic acids encoding variant CBH I polypeptides and host cells that recombinantly express the variant CBH I polypeptides.Type: ApplicationFiled: October 5, 2012Publication date: September 25, 2014Applicant: Bp Corporation North America Inc.Inventors: Sarah Richardson Hanson, Justin T. Stege, Cecilia Cheng, Peter Luginbuhl
-
Publication number: 20140286934Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.Type: ApplicationFiled: January 30, 2014Publication date: September 25, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
-
Publication number: 20140289904Abstract: Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or to increase the level of malonyl CoA in the organism, and in one aspect, to inhibit KASII or KASIII.Type: ApplicationFiled: March 21, 2013Publication date: September 25, 2014Applicant: DSM IP Assets B.V.Inventors: James G. METZ, Jerry M. Kuner, James Casey Lippmeier
-
Publication number: 20140286951Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Publication number: 20140289905Abstract: Provided are isolated polypeptides having xylanase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: November 9, 2012Publication date: September 25, 2014Applicant: Novozymes Inc.Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
-
Publication number: 20140286935Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicant: Glaxosmithkline Intellectual Property Development LimitedInventors: Paul HAMBLIN, Alan Lewis, Thomas Matthew Webb